Literature DB >> 2556484

Low molecular weight heparin (Alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures.

M Pini1, A Tagliaferri, C Manotti, F Lasagni, E Rinaldi, A G Dettori.   

Abstract

Efficacy and safety of a low molecular weight heparin (Alfa LMWH) was compared with unfractionated heparin (UFH) in the prevention of post-operative venous thromboembolism after hip fractures. Forty-nine patients were randomized to treatment with Alfa LMWH 7500 anti-Xa coagulometric units twice daily or with UFH 5000 IU t.i.d. Screening for thrombosis was performed with 125-I-fibrinogen leg scanning and strain-gauge plethysmography. Positive results were confirmed by venography. Five patients in the Alfa LMWH group (20 per cent) developed venographycally proven deep vein thrombosis (DVT) versus seven (29 per cent) in the UFH group. One pulmonary embolism and two deaths occurred in the UFH group and none in the LMWH group. No differences in haemorrhagic complications and blood loss indices were observed. Alfa LMWH appears to be a promising drug for prevention of venous thromboembolism after orthopaedic surgery. A "flexible" schedule of administration is proposed on the basis of the results of plasma anti-Xa assays.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556484

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  10 in total

Review 1.  Physiological changes due to age. Implications for the prevention and treatment of thrombosis in older patients.

Authors:  M T Nurmohamed; H R Büller; J W ten Cate
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

2.  Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery.

Authors:  R Ferriols-Lisart; F Ferriols-Lisart; V Jiménez-Torres
Journal:  Pharm World Sci       Date:  2002-06

3.  Low molecular weight heparin in prevention of perioperative thrombosis.

Authors:  A Leizorovicz; M C Haugh; F R Chapuis; M M Samama; J P Boissel
Journal:  BMJ       Date:  1992-10-17

4.  Prevention of deep vein thrombosis in patients with hip fractures: low molecular weight heparin versus dextran.

Authors:  D Oertli; P Hess; M Durig; U Laffer; R Fridrich; K Jaeger; R Kaufmann; F Harder
Journal:  World J Surg       Date:  1992 Sep-Oct       Impact factor: 3.352

Review 5.  Low molecular weight heparins. An objective overview.

Authors:  D Hoppensteadt; J M Walenga; J Fareed
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

Review 6.  Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.

Authors:  J E Frampton; D Faulds
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

7.  American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Authors:  David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm
Journal:  Blood Adv       Date:  2019-12-10

Review 8.  Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Update on the clinical use of the low-molecular-weight heparin, parnaparin.

Authors:  Giuseppe Camporese; Enrico Bernardi; Franco Noventa
Journal:  Vasc Health Risk Manag       Date:  2009-10-12

Review 10.  Clinical use of parnaparin in major and minor orthopedic surgery: a review.

Authors:  Stefano Bugamelli; Elena Zangheri; Milena Montebugnoli; Lucia Guerra
Journal:  Vasc Health Risk Manag       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.